Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jan;98(3):e13788.
doi: 10.1097/MD.0000000000013788.

Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis

Yi Zhang  1 , Bo Chen  2 , Lijuan Wang  3 , Rong Wang  1 , Xianjin Yang  1
Affiliations
Meta-Analysis

Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis

Yi Zhang et al. Medicine (Baltimore). 2019 Jan.

Abstract

Background: The prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established.

Methods: Relevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up.

Results: In total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4-1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54-2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69-2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02-1.85, P < .001; 1 study, 919 patients).

Conclusion: Our data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.

PubMed Disclaimer

Conflict of interest statement

The author (s) of this work have nothing to disclose and the authors declare that there are no competing interests regarding the publication of this paper.

Figures

Figure 1
Figure 1
Flow diagram of included studies for this meta-analysis.
Figure 2
Figure 2
Forest plot for the association between SII and OS in lung cancer.
Figure 3
Figure 3
Subgroup meta-analysis of the association between SII and OS in lung cancer.
Figure 4
Figure 4
Publication bias assessment. (A) Begg funnel plot. (B) Egger publication bias plot.
Figure 5
Figure 5
Sensitivity analysis.
See this image and copyright information in PMC

References

    1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016;893:1–9. - PubMed
    1. Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis 2011;3:122–33. - PMC - PubMed
    1. Moro-Sibilot D, Smit E, de Castro Carpeño J, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer 2015;88:215–22. - PubMed
    1. Lu H, Jiang Z. Advances in antibody therapeutics targeting small-cell lung cancer. Adv Clin Exp Med 2018;27:1317–23. - PubMed
    1. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008;3:917–28. - PubMed